Three Hoosier Cancer Research Network (HCRN) investigator-initiated clinical trials were highlighted during the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting in Chicago.

HCRN BRE18-360

Poster Session: Phase I/II study of stereotactic radiosurgery with concurrent Olaparib followed by adjuvant durvalumab and physician’s choice systemic therapy in patients with breast cancer brain metastases.

Presenter: Colette Shen, MD, PhD | University of North Carolina at Chapel Hill

Date: June 4, 2023 | Time: 8:00 AM – 11:00AM CT | Location: Hall A

Session Title: Breast Cancer – Metastatic | Track: Breast Cancer | Sub track: Triple-Negative  

Abstract: TPS1133 | Poster # 343a

HCRN GU16-260

Determinants of resistance to nivolumab (nivo) monotherapy investigated through genomic and transcriptomic analysis of renal cell carcinoma (RCC) tumors from the HCRN GU16-260

Presenter: David A. Braun, MD, PhD | School of Medicine, Yale University

Date: June 3, 2023 | Time: 8:00 AM CT – 11:00 AM CT | Location: Hall A

Session: Genitourinary Cancer – Kidney and Bladder | Track: Genitourinary Cancer – Kidney and Bladder | Sub Track: Biologic Correlates

Abstract: 4524 | Poster # 16

HCRN GU16-260

Biomarkers of response to first-line nivolumab therapy in patients with advanced renal cell carcinoma (RCC) enrolled in the HCRN GU16-260 trial.

Presenter: Nourhan El Ahmar, MD | Brigham and Women’s Hospital

Date: June 3, 2023 | Time: 8:00 AM CT – 11:00 AM CT | Location: Hall A

Session: Genitourinary Cancer – Kidney and Bladder | Track: Genitourinary Cancer – Kidney and Bladder | Sub Track: Kidney Cancer

Abstract: 4549 | Poster # 41

Meet us at ASCO

HCRN will host in-person meetings for the Breast Cancer, Gastrointestinal, Thoracic, Melanoma and the Genitourinary Clinical Trial Working Group during ASCO 2023. To request a calendar invitation, please contact Debbie Schlegel at dschlegel@hoosiercancer.org. Some meetings will have a virtual option for those who cannot attend in person.

Through HCRN’s Clinical Trial Working Groups, investigators receive scientific input from their peers to ensure protocols are well designed and to gauge interest among potential study sites. HCRN facilitates regular virtual meetings to keep all members of the study team apprised of a study’s progress and to address any concerns or challenges that arise.

About Hoosier Cancer Research Network:

Hoosier Cancer Research Network conducts innovative cancer research in collaboration with academic and community physicians and scientists across the United States. The organization provides comprehensive clinical trial management and support, from conception through publication. Created in 1984 as a program of the Walther Cancer Institute, Hoosier Cancer Research Network became an independent nonprofit clinical research organization in 2007. Since its founding, Hoosier Cancer Research Network has conducted more than 230 trials in a variety of cancer types and supportive care, resulting in more than 350 publications. More than 9,000 subjects have participated in Hoosier Cancer Research Network clinical trials.